Skip to main content

Table 3 Changes of the RQLQ Domains at 4 Weeks From Baseline

From: Persistent Allergic Rhinitis and the XPERT Study

  Placebo Change Levocetirizine (5 mg) Change Difference versus Placebo (95% CI)
Domain N* Adjusted Mean† (SEM) N* Adjusted Mean† (SEM) Adjusted Mean P
Activities 241 −1.36 (0.10) 248 −2.08 (0.10) 0.73 (0.47-0.99) <0.001
Emotions 252 −0.81 (0.07) 257 −1.16 (0.07) 0.35 (0.17-0.54) <0.001
Eye symptoms 252 −0.91 (0.09) 257 −1.40 (0.09) 0.48 (0.26-0.70) <0.001
Non-hay fever symptoms 252 −0.83 (0.08) 257 −1.21 (0.08) 0.38 (0.18-0.57) <0.001
Nasal symptoms 252 −1.10 (0.09) 257 −1.64 (0.09) 0.54 (0.31-0.77) <0.001
Practical problems 252 −1.50 (0.10) 257 −2.06 (0.10) 0.56 (0.30-0.82) <0.001
Sleep 252 −0.86 (0.09) 257 −1.35 (0.09) 0.50 (0.27-0.73) <0.001
  1. *Number of ITT patients with nonmissing values at baseline and under treatment.
  2. †Mean change from baseline, adjusted for baseline score and country.